ABSTRACT
Facing the COVID-19 pandemic, testing individuals in order to promptly isolate positive people is one of the key actions. One approach to rapid testing might be to consider the olfactory capacities of trained detection dogs in order to develop a non-invasive, rapid and cheap mass detection approach, through the Volatile Organic Compounds (VOCs) signature of SARS-CoV-2 infection.
The goal of this study was to determine the individual values of sensitivity and specificity of trained dogs when performing olfactory detection of COVID-19 on axillary sweat samples. Seven dogs were used to sniff a total of 218 samples (62 COVID-19 positive and 156 COVID-19 negative samples), based on a randomised and double-blinded protocol carried out on olfaction cone line-ups. To ensure a wide olfactory range as close as possible to operational conditions, the samples were retrieved from 13 different sites.
Sensitivities varied from 87% to 94% for 6 dogs, and were above 90% for 3 of them. Only one dog, whose sensitivity was 60%, was not selected to subsequently enter the operational stage. Specificities varied from 78% to 92%, with 6 dogs over 85% and 4 dogs over 90%.
Based on the calculated sensitivity and specificity for each dog, positive and negative predictive values (PPV and NPV) were calculated according to several prevalence rates of SARS-CoV-2 scenarii, and were compared to PPV and NPV of an “almost perfect” diagnostic tool. For 6 out of the 7 dogs, and for a prevalence rate of SARS-CoV-2 lower or equal than 40%, the NPV of the dogs were virtually the same as the one of the “almost perfect” tool. Along with other studies on olfactory detection of COVID-19 by dogs these positive and encouraging results suggest that olfactory dogs may play an important part in mass COVID-19 pre-testing situations.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Funding has been auto supported by the involved institutions
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was carried out in strict accordance with the recommendations published in the Guide for the care and use of animals edited by French laws (articles R214-87 to R214-137 of the rural code), updates by decree 2013-118 and five decrees edited on February 1st 2013. The protocol was approved by the committee on the ethics of animal experiments of the Ecole Nationale Veterinaire d Alfort (Alfort School of Veterinary Medicine) and by the Protection of Persons Committee (CPP) of the Ile-de-France on march 30th 2020. It also follows the rules of the French Public Health Code (article L1121-1/2). This research is part of the study COVIDEF promoted by Assistance Publique Hopitaux de Paris (Parisian hospitals) led by Professor Hausfater, as COVIDOG (Cohort of patients infected by the virus SARS-CoV-2 or suspected to be infected)for the samples coming from AP-HP, and of the study VOC-COVID-Diag promoted by hopital Foch (Suresnes) led by Professor Devillier. The latter study has been approved by the CPP Nord Ouest IV on october 8th 2020.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
This research has been supported by German Federal Ministry of Health (BMG) COVID-19 research and development funding to World Health Organization. The authors alone are responsible for the views expressed in this publication and they do not necessarily represent the views, decisions or policies of WHO.
Data Availability
All the data described in this article are available on request